Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Pharming
Pharming
(PHAR)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Annual sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Ruconest
Conestat alfa
2014-07-16
Hereditary angioedemas
Joenja
Leniolisib
2023-03-24
2032
Primary immunodeficiency diseases
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Conestat alfa
neuromyelitis optica
,
cardiovascular diseases
,
stroke
,
cerebrovascular disorders
,
ischemia
,
vascular diseases
,
cerebral infarction
,
brain infarction
,
brain ischemia
,
reperfusion injury
,
renal insufficiency
,
kidney transplantation
,
acute kidney injury
,
chronic renal insufficiency
,
chronic kidney failure
,
delayed graft function
,
graft rejection
,
ischemic stroke
,
renal cell carcinoma
,
urologic neoplasms
,
carcinoma
,
neoplasms
,
non-small-cell lung carcinoma
,
stomach neoplasms
,
head and neck neoplasms
,
lung neoplasms
,
squamous cell carcinoma of head and neck
,
melanoma
,
transitional cell carcinoma
,
squamous cell carcinoma
,
mouth neoplasms
,
oropharyngeal neoplasms
,
squamous cell neoplasms
,
neoplasms by histologic type
,
neoplasms by site
,
glandular and epithelial neoplasms
,
hypopharyngeal neoplasms
,
infections
,
coronavirus infections
,
communicable diseases
,
fatigue
,
traumatic brain injuries
,
craniocerebral trauma
,
brain injuries
,
myocardial infarction
,
non-st elevated myocardial infarction
,
infarction
,
aortic valve stenosis
,
heart valve diseases
,
subarachnoid hemorrhage
,
inflammation
,
sepsis
,
wounds and injuries
,
endotoxemia
,
multiple organ failure
,
innate immunity
,
immune system diseases
,
hypersensitivity
,
edema
,
hereditary angioedemas
,
angioedema
,
hereditary angioedema types i and ii
,
inborn genetic diseases
,
covid-19
,
chronic fatigue syndrome
,
drug-related side effects and adverse reactions
,
primary immunodeficiency diseases
,
common variable immunodeficiency
,
asthma
,
rare diseases
,
immunologic tests
,
graft vs host disease
,
systemic mastocytosis
,
urticaria
,
mastocytosis
Leniolisib
sjogren's syndrome
,
syndrome
,
primary immunodeficiency diseases
,
immunologic deficiency syndromes
,
common variable immunodeficiency
,
lymphadenopathy
NAPAZIMONE
mitochondrial diseases
,
diabetes mellitus
,
muscular diseases
,
muscle weakness
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use